The elusive antifibrotic macrophage

Frontiers in Medicine

Volumn 2, Issue NOV, 2015, Pages

  Adhyatmika, Adhyatmika ^a   Putri, Kurnia S S ^a,b   Beljaars, Leonie ^a   Melgert, Barbro N ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antifibrotic; Cathepsin K; Fibrosis; Macrophages; MMP; Monocytes; Polarization; Resolution

Indexed keywords

EID: 84977498130     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2015.00081     Document Type: Review

References (127)

1. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 214:199-210. doi:10.1002/path.2277
2. Noble PW, Homer RJ. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol (2005) 33:113-20. doi:10.1165/rcmb.F301
3. Wynn T, Ramalingam T. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med (2012) 18:1028-40. doi:10.1038/nm.2807
4. Pellicoro A, Ramachandran P, Iredale J, Fallowfield J. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol (2014) 14:181-94. doi:10.1038/nri3623
5. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci (2014) 71:549-74. doi:10.1007/s00018-013-1349-6
6. McKleroy W, Lee T-H, Atabai K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol (2013) 304:L709-21. doi:10.1152/ajplung.00418.2012
7. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol (2011) 300:G723-8. doi:10.1152/ajpgi.00414.2010
8. Gibbons MA, MacKinnon AC, Ramachandran P, Dhaliwal K, Duffin R, Phythian-Adams AT, et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med (2011) 184:569-81. doi:10.1164/rccm.201010-1719oc
9. Song E, Ouyang N, Hörbelt M, Antus B, Wang M, Exton MS. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol (2000) 204:19-28. doi:10.1006/cimm.2000.1687
10. Boorsma CE, Draijer C, Melgert BN. Macrophage heterogeneity in respiratory diseases. Mediators Inflamm (2013) 2013:769214. doi:10.1155/2013/769214
11. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest (2005) 115:56-65. doi:10.1172/JCI22675
12. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol (2005) 5:953-64. doi:10.1038/nri1733
13. Mills CD. Anatomy of a discovery: m1 and m2 macrophages. Front Immunol (2015) 6:212. doi:10.3389/fimmu.2015.00212
14. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep (2014) 6:13. doi:10.12703/P6-13
15. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci (2008) 13:453-61. doi:10.2741/2692
16. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41:14-20. doi:10.1016/j.immuni.2014.06.008
17. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog (2009) 5:e1000371. doi:10.1371/journal.ppat.1000371
18. Ramachandran P, Pellicoro A, Vernon M, Boulter L, Aucott R, Ali A, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U S A (2012) 109:E3186-95. doi:10.1073/pnas.1119964109
19. Wynn T, Chawla A, Pollard J. Macrophage biology in development, homeostasis and disease. Nature (2013) 496:445-55. doi:10.1038/nature12034
20. Anders H-J, Ryu M. Renal microenvironments and macrophage phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int (2011) 80:915-25. doi:10.1038/ki.2011.217
21. Wermuth PJ, Jimenez SA. The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases. Clin Transl Med (2015) 4:2. doi:10.1186/s40169-015-0047-4
22. Pesce JT, Ramalingam TR, Wilson MS, Mentink-Kane MM, Thompson RW, Cheever AW, et al. Retnla (relmalpha/fizz1) suppresses helminth-induced Th2-type immunity. PLoS Pathog (2009) 5:e1000393. doi:10.1371/journal.ppat.1000393
23. Madala SK, Edukulla R, Davis KR, Schmidt S, Davidson C, Kitzmiller JA, et al. Resistin-like molecule a1 (Fizz1) recruits lung dendritic cells without causing pulmonary fibrosis. Respir Res (2012) 13:51. doi:10.1186/1465-9921-13-51
24. Liu T, Yu H, Ullenbruch M, Jin H, Ito T, Wu Z, et al. The in vivo fibrotic role of FIZZ1 in pulmonary fibrosis. PLoS One (2014) 9:e88362. doi:10.1371/journal.pone.0088362
25. Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med (2013) 210:1977-92. doi:10.1084/jem.20131199
26. Yona S, Kim K-W, Wolf Y, Mildner A, Varol D, Breker M, et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. Immunity (2013) 38:79-91. doi:10.1016/j.immuni.2012.12.001
27. Hashimoto D, Chow A, Noizat C, Teo P, Beasley M, Leboeuf M, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 38:792-804. doi:10.1016/j.immuni.2013.04.004
28. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science (2012) 336:86-90. doi:10.1126/science.1219179
29. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity (2013) 39:599-610. doi:10.1016/j.immuni.2013.08.007
30. Hoeffel G, Wang Y, Greter M, See P, Teo P, Malleret B, et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J Exp Med (2012) 209:1167-81. doi:10.1084/jem.20120340
31. Epelman S, Lavine KJ, Beaudin AE, Sojka DK, Carrero JA, Calderon B, et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity (2014) 40:91-104. doi:10.1016/j.immuni.2013.11.019
32. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity (2014) 41:21-35. doi:10.1016/j.immuni.2014.06.013
33. Gundra UM, Girgis NM, Ruckerl D, Jenkins S, Ward LN, Kurtz ZD, et al. Alternatively activated macrophages derived from monocytes and tissue macrophages are phenotypically and functionally distinct. Blood (2014) 123:e110-22. doi:10.1182/blood-2013-08-520619
34. Vannella KM, Barron L, Borthwick LA, Kindrachuk KN, Narasimhan PB, Hart KM, et al. Incomplete deletion of IL-4Ra by LysM(Cre) reveals distinct subsets of M2 macrophages controlling inflammation and fibrosis in chronic schistosomiasis. PLoS Pathog (2014) 10:e1004372. doi:10.1371/journal.ppat.1004372
35. Hoeffel G, Chen J, Lavin Y, Low D, Almeida F, See P, et al. C-Myb+ erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity (2015) 42(4):665-78. doi:10.1016/j.immuni.2015.03.011
36. McGrath KE, Frame JM, Fegan KH, Bowen JR, Conway SJ, Catherman SC, et al. Distinct sources of hematopoietic progenitors emerge before HSCs and provide functional blood cells in the mammalian embryo. Cell Rep (2015) 11:1892-904. doi:10.1016/j.celrep.2015.05.036
37. Palis J. Primitive and definitive erythropoiesis in mammals. Front Physiol (2014) 5:3. doi:10.3389/fphys.2014.00003
38. Hashimoto D, Miller J, Merad M. Dendritic cell and macrophage heterogeneity in vivo. Immunity (2011) 35(3):323-35. doi:10.1016/j.immuni.2011.09.007
39. Bogunovic M, Ginhoux F, Helft J, Shang L, Hashimoto D, Greter M, et al. Origin of the lamina propria dendritic cell network. Immunity (2009) 31:513-25. doi:10.1016/j.immuni.2009.08.010
40. Gross M, Salame T-M, Jung S. Guardians of the gut-murine intestinal macrophages and dendritic cells. Front Immunol (2015) 6:254. doi:10.3389/fimmu.2015.00254
41. Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci (2013) 7:45. doi:10.3389/fncel.2013.00045
42. Haniffa M, Ginhoux F, Wang X-N, Bigley V, Abel M, Dimmick I, et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. J Exp Med (2009) 206:371-85. doi:10.1084/jem.20081633
43. Tamoutounour S, Guilliams M, Montanana Sanchis F, Liu H, Terhorst D, Malosse C, et al. Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity (2013) 39:925-38. doi:10.1016/j.immuni.2013.10.004
44. Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature (2015) 518:547-51. doi:10.1038/nature13989
45. Carlin LM, Stamatiades EG, Auffray C, Hanna RN, Glover L, Vizcay-Barrena G, et al. Nr4a1-dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell (2013) 153:362-75. doi:10.1016/j.cell.2013.03.010
46. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, Kayal S, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science (2007) 317:666-70. doi:10.1126/science.1142883
47. Hettinger J, Richards DM, Hansson J, Barra MM, Joschko A-C, Krijgsveld J, et al. Origin of monocytes and macrophages in a committed progenitor. Nat Immunol (2013) 14:821-30. doi:10.1038/ni.2638
48. Hanna RN, Carlin LM, Hubbeling HG, Nackiewicz D, Green AM, Punt JA, et al. The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C-monocytes. Nat Immunol (2011) 12:778-85. doi:10.1038/ni.2063
49. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med (2007) 204:1057-69. doi:10.1084/jem.20070075
50. Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ Res (2014) 114:1611-22. doi:10.1161/CIRCRESAHA.114.303204
51. Ingersoll MA, Spanbroek R, Lottaz C, Gautier EL, Frankenberger M, Hoffmann R, et al. Comparison of gene expression profiles between human and mouse monocyte subsets. Blood (2010) 115:e10-9. doi:10.1182/blood-2009-07-235028
52. Liaskou E, Zimmermann HW, Li K-K, Oo YH, Suresh S, Stamataki Z, et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology (2013) 57:385-98. doi:10.1002/hep.26016
53. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology (2009) 50:261-74. doi:10.1002/hep.22950
54. Lin SL, Castaño AP, Nowlin BT, Lupher ML, Duffield JS. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol (2009) 183:6733-43. doi:10.4049/jimmunol.0901473
55. Falkenham A, de Antueno R, Rosin N, Betsch D, Lee TD, Duncan R, et al. Nonclassical resident macrophages are important determinants in the development of myocardial fibrosis. Am J Pathol (2015) 185:927-42. doi:10.1016/j.ajpath.2014.11.027
56. Ji W-J, Ma Y-Q, Zhou X, Zhang Y-D, Lu R-Y, Sun H-Y, et al. Temporal and spatial characterization of mononuclear phagocytes in circulating, lung alveolar and interstitial compartments in a mouse model of bleomycin-induced pulmonary injury. J Immunol Methods (2014) 403:7-16. doi:10.1016/j.jim.2013.11.012
57. Mitchell C, Couton D, Couty J-P, Anson M, Crain A-M, Bizet V, et al. Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol (2009) 174:1766-75. doi:10.2353/ajpath.2009.080632
58. Shechter R, Raposo C, London A, Sagi I, Schwartz M. The glial scar-monocyte interplay: a pivotal resolution phase in spinal cord repair. PLoS One (2011) 6:e27969. doi:10.1371/journal.pone.0027969
59. Tighe RM, Liang J, Liu N, Jung Y, Jiang D, Gunn MD, et al. Recruited exudative macrophages selectively produce CXCL10 after noninfectious lung injury. Am J Respir Cell Mol Biol (2011) 45:781-8. doi:10.1165/rcmb.2010-0471OC
60. Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE, Luedde T, et al. The fractalkine receptor CX-CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology (2010) 52:1769-82. doi:10.1002/hep.23894
61. Barnes MA, McMullen MR, Roychowdhury S, Madhun NZ, Niese K, Olman MA, et al. Macrophage migration inhibitory factor is required for recruitment of scar-associated macrophages during liver fibrosis. J Leukoc Biol (2015) 97:161-9. doi:10.1189/jlb.3A0614-280R
62. Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 59:1060-72. doi:10.1002/hep.26783
63. Stout R, Jiang C, Matta B, Tietzel I, Watkins S, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol (2005) 175:342-9. doi:10.4049/jimmunol.175.1.342
64. Khalil N, Corne S, Whitman C, Yacyshyn H. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol (1996) 15:252-9. doi:10.1165/ajrcmb.15.2.8703482
65. Reddy AT, Lakshmi SP, Zhang Y, Reddy RC. Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages. FASEB J (2014) 28:5299-310. doi:10.1096/fj.14-256263
66. Srivastava M, Steinwede K, Kiviranta R, Morko J, Hoymann H-G, Länger F, et al. Overexpression of cathepsin K in mice decreases collagen deposition and lung resistance in response to bleomycin-induced pulmonary fibrosis. Respir Res (2008) 9:54. doi:10.1186/1465-9921-9-54
67. Beljaars L, Schippers M, Reker-Smit C, Martinez FO, Helming L, Poelstra K, et al. Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans. Front Immunol (2014) 5:430. doi:10.3389/fimmu.2014.00430
68. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS, et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol (2007) 178:5288-95. doi:10.4049/jimmunol.178.8.5288
69. Borel O, Gineyts E, Bertholon C, Garnero P. Cathepsin K preferentially solubilizes matured bone matrix. Calcif Tissue Int (2012) 91:32-9. doi:10.1007/s00223-012-9604-7
70. Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol (2011) 7:447-56. doi:10.1038/nrrheum.2011.77
71. Fonovic M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys Acta (2014) 1840:2560-70. doi:10.1016/j.bbagen.2014.03.017
72. Huang W-C, Sala-Newby GB, Susana A, Johnson JL, Newby AC. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-κB. PLoS One (2012) 7:e42507. doi:10.1371/journal.pone.0042507
73. Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, et al. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology (2011) 53:2003-15. doi:10.1002/hep.24315
74. Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol (2010) 298:G323-34. doi:10.1152/ajpgi.00394.2009
75. Cabrera S, Gaxiola M, Arreola JL, Ramírez R, Jara P, D'Armiento J, et al. Overexpression of MMP9 in macrophages attenuates pulmonary fibrosis induced by bleomycin. Int J Biochem Cell Biol (2007) 39:2324-38. doi:10.1016/j.biocel.2007.06.022
76. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science (2015) 347:1260419. doi:10.1126/science.1260419
77. Van den Brûle S, Misson P, Bühling F, Lison D, Huaux F. Overexpression of cathepsin K during silica-induced lung fibrosis and control by TGF-beta. Respir Res (2005) 6:84. doi:10.1186/1465-9921-6-84
78. Bühling F, Röcken C, Brasch F, Hartig R, Yasuda Y, Saftig P, et al. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol (2004) 164:2203-16. doi:10.1016/S0002-9440(10)63777-7
79. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest (2008) 118:3012-24. doi:10.1172/JCI32750
80. Rohani MG, Parks WC. Matrix remodeling by MMPs during wound repair. Matrix Biol (2015) 44-46C:113-21. doi:10.1016/j.matbio.2015.03.002
81. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol (2001) 17:463-516. doi:10.1146/annurev.cellbio.17.1.463
82. Engelholm LH, List K, Netzel-Arnett S, Cukierman E, Mitola DJ, Aaronson H, et al. uPARAP/Endo180 is essential for cellular uptake of collagen and promotes fibroblast collagen adhesion. J Cell Biol (2003) 160:1009-15. doi:10.1083/jcb.200211091
83. López-Guisa JM, Cai X, Collins SJ, Yamaguchi I, Okamura DM, Bugge TH, et al. Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol (2012) 23:236-51. doi:10.1681/ASN.2011030310
84. Boskovic J, Arnold JN, Stilion R, Gordon S, Sim RB, Rivera-Calzada A, et al. Structural model for the mannose receptor family uncovered by electron microscopy of Endo180 and the mannose receptor. J Biol Chem (2006) 281:8780-7. doi:10.1074/jbc.M513277200
85. Atabai K, Jame S, Azhar N, Kuo A, Lam M, McKleroy W, et al. Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages. J Clin Invest (2009) 119:3713-22. doi:10.1172/JCI40053
86. Creasy BM, McCoy KL. Cytokines regulate cysteine cathepsins during TLR responses. Cell Immunol (2011) 267:56-66. doi:10.1016/j.cellimm.2010.11.004
87. Balce DR, Li B, Allan ER, Rybicka JM, Krohn RM, Yates RM. Alternative activation of macrophages by IL-4 enhances the proteolytic capacity of their phagosomes through synergistic mechanisms. Blood (2011) 118:4199-208. doi:10.1182/blood-2011-01-328906
88. Yu Z, Xie M, Fan X, Jia J. Interferon a2b increases MMP-13 and IL-10 expression in Kupffer cells through MAPK signaling pathways. Hepatogastroenterology (2015) 62:350-4
89. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood (2007) 109:1026-33. doi:10.1182/blood-2006-05-021634
90. Zagórska A, Través PG, Lew ED, Dransfield I, Lemke G. Diversification of TAM receptor tyrosine kinase function. Nat Immunol (2014) 15:920-8. doi:10.1038/ni.2986
91. Rüeger S, Bochud P-Y, Dufour J-F, Müllhaupt B, Semela D, Heim MH, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut (2014) 64(10):1605-15. doi:10.1136/gutjnl-2014-306997
92. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology (2012) 143:1244-52.e1_12. doi:10.1053/j.gastro.2012.07.097
93. Yoon Y-S, Kim S-Y, Kim M-J, Lim J-H, Cho M-S, Kang JL. PPAR? activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines. Mucosal Immunol (2015) 8(5):1031-46. doi:10.1038/mi.2014.130
94. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest (2009) 89:47-58. doi:10.1038/labinvest.2008.104
95. Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, et al. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet. Hepatol Res (2005) 32:235-42. doi:10.1016/j.hepres.2005.05.008
96. Ihm S-H, Chang K, Kim H-Y, Baek SH, Youn H-J, Seung K-B, et al. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor. Basic Res Cardiol (2010) 105:399-407. doi:10.1007/s00395-009-0071-x
97. Higashi K, Oda T, Kushiyama T, Hyodo T, Yamada M, Suzuki S, et al. Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology (Carlton) (2010) 15:327-35. doi:10.1111/j.1440-1797.2009.01253.x
98. Yang L, Stimpson SA, Chen L, Wallace Harrington W, Rockey DC. Effectiveness of the PPARγ agonist, GW570, in liver fibrosis. Inflamm Res (2010) 59:1061-71. doi:10.1007/s00011-010-0226-0
99. Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, et al. A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses. Ann Rheum Dis (2014) 73:446-54. doi:10.1136/annrheumdis-2012-202716
100. Attia YM, Elalkamy EF, Hammam OA, Mahmoud SS, El-Khatib AS. Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection. Parasit Vectors (2013) 6:199. doi:10.1186/1756-3305-6-199
101. Piguet PF, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur Respir J (1994) 7:515-8. doi:10.1183/09031936.94.07030515
102. Kitamura K, Nakamoto Y, Akiyama M, Fujii C, Kondo T, Kobayashi K, et al. Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis. Lab Invest (2002) 82:571-83. doi:10.1038/labinvest.3780452
103. Rojanasakul Y, Weissman DN, Shi X, Castranova V, Ma JK, Liang W. Antisense inhibition of silica-induced tumor necrosis factor in alveolar macrophages. J Biol Chem (1997) 272:3910-4. doi:10.1074/jbc.272.7.3910
104. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH. IL-1beta and TNF-alpha upregulate angiotensin II type 1 (AT1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. J Mol Cell Cardiol (2005) 38:505-15. doi:10.1016/j.yjmcc.2004.12.015
105. Meldrum KK, Misseri R, Metcalfe P, Dinarello CA, Hile KL, Meldrum DR. TNF-alpha neutralization ameliorates obstruction-induced renal fibrosis and dysfunction. Am J Physiol Regul Integr Comp Physiol (2007) 292:R1456-64. doi:10.1152/ajpregu.00620.2005
106. Redente EF, Keith RC, Janssen W, Henson PM, Ortiz LA, Downey GP, et al. Tumor necrosis factor-a accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages. Am J Respir Cell Mol Biol (2014) 50:825-37. doi:10.1165/rcmb.2013-0386oc
107. Zhang Y, Lee TC, Guillemin B, Yu MC, Rom WN. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol (1993) 150:4188-96
108. Woodcock HV, Maher TM. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 6:16. doi:10.12703/P6-16
109. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan Y-T, et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation (2009) 119:1386-97. doi:10.1161/CIRCULATIONAHA.108.802918
110. Morimoto Y, Gai Z, Tanishima H, Kawakatsu M, Itoh S, Hatamura I, et al. TNF-alpha deficiency accelerates renal tubular interstitial fibrosis in the late stage of ureteral obstruction. Exp Mol Pathol (2008) 85:207-13. doi:10.1016/j.yexmp.2008.08.003
111. Lemos DR, Babaeijandaghi F, Low M, Chang C-K, Lee ST, Fiore D, et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med (2015) 21:786-94. doi:10.1038/nm.3869
112. Sun L, Louie MC, Vannella KM, Wilke CA, LeVine AM, Moore BB, et al. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol (2011) 300:L341-53. doi:10.1152/ajplung.00122.2010
113. Barbarin V, Arras M, Misson P, Delos M, McGarry B, Phan SH, et al. Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice. Am J Respir Cell Mol Biol (2004) 31:78-85. doi:10.1165/rcmb.2003-0299OC
114. Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology (2014) 146:1339-50.e1. doi:10.1053/j.gastro.2014.01.061
115. Heinrichs D, Knauel M, Offermanns C, Berres M-L, Nellen A, Leng L, et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci U S A (2011) 108:17444-9. doi:10.1073/pnas.1107023108
116. Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med (2007) 13:587-96. doi:10.1038/nm1567
117. Liang Y, Luo J, Lu Q, Zhou Y, Wu H, Zheng D, et al. Gene profile of chemokines on hepatic stellate cells of schistosome-infected mice and antifibrotic roles of CXCL9/10 on liver non-parenchymal cells. PLoS One (2012) 7:e42490. doi:10.1371/journal.pone.0042490
118. Tager A, Kradin R, LaCamera P, Bercury S, Campanella G, Leary C, et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol (2004) 31:395404. doi:10.1165/rcmb.2004-0175OC
119. Poelstra K, Beljaars L, Melgert BN. Cell-specific delivery of biologicals: problems, pitfalls and possibilities of antifibrotic compounds in the liver. Drug Discov Today (2013) 18:1237-42. doi:10.1016/j.drudis.2013.05.013
120. Madsen DH, Jürgensen HJ, Ingvarsen S, Melander MC, Vainer B, Egerod KL, et al. Endocytic collagen degradation: a novel mechanism involved in protection against liver fibrosis. J Pathol (2012) 227:94-105. doi:10.1002/path.3981
121. Madsen DH, Leonard D, Masedunskas A, Moyer A, Jürgensen HJ, Peters DE, et al. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol (2013) 202:951-66. doi:10.1083/jcb.201301081
122. Wittrant Y, Theoleyre S, Couillaud S, Dunstan C, Heymann D, Redini F. Regulation of osteoclast protease expression by RANKL. Biochem Biophys Res Commun (2003) 310:774-8. doi:10.1016/j.bbrc.2003.09.084
123. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem (2004) 279:45969-79. doi:10.1074/jbc.M408795200
124. Sundaram K, Nishimura R, Senn J, Youssef R, London S, Reddy S. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res (2006) 313:168-78. doi:10.1016/j.yexcr.2006.10.001
125. Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Investig (2004) 114:291299. doi:10.1172/JCI16861
126. Guilherme RF, Xisto DG, Kunkel SL, Freire-de-Lima CG, Rocco PR, Neves JS, et al. Pulmonary antifibrotic mechanisms aspirin-triggered lipoxin A(4) synthetic analog. Am J Respir Cell Mol Biol (2013) 49:1029-37. doi:10.1165/rcmb.2012-0462OC
127. Alagesan S, Griffin MD. Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor. Kidney Int (2014) 85:730-3. doi:10.1038/ki.2013.405